Premier Asset Management LLC trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,623 shares of the medical research company’s stock after selling 500 shares during the period. Thermo Fisher Scientific makes up 1.9% of Premier Asset Management LLC’s investment portfolio, making the stock its 28th largest holding. Premier Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $8,443,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Shine Investment Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $113,000. Ropes Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares during the last quarter. Atlantic Trust LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $138,000. Finally, Grove Bank & Trust increased its holdings in Thermo Fisher Scientific by 19.9% during the second quarter. Grove Bank & Trust now owns 860 shares of the medical research company’s stock valued at $150,000 after buying an additional 143 shares during the last quarter. 86.05% of the stock is owned by hedge funds and other institutional investors.

Shares of Thermo Fisher Scientific Inc. (TMO) opened at $193.89 on Wednesday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The stock has a market cap of $77,620.68, a price-to-earnings ratio of 21.27, a PEG ratio of 1.77 and a beta of 1.06. Thermo Fisher Scientific Inc. has a 52 week low of $139.88 and a 52 week high of $201.20.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 earnings per share. research analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

In other news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.49% of the company’s stock.

A number of analysts have commented on the stock. Leerink Swann reaffirmed an “outperform” rating and set a $200.00 target price (down from $216.00) on shares of Thermo Fisher Scientific in a report on Monday, December 4th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 target price for the company in a report on Tuesday, October 31st. Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. Jefferies Group reaffirmed a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price for the company. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $205.21.

ILLEGAL ACTIVITY WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/20/premier-asset-management-llc-decreases-stake-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.